Caricamento...
Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
Rebound disease following cessation of disease modifying treatment (DMT) has been reported in people with both relapsing and progressive multiple sclerosis (pwRMS, pwPMS) questioning strict separation between these two phenotypes. While licensed DMT is available for pwRMS to counter rebound disease,...
Salvato in:
| Pubblicato in: | Ann Clin Transl Neurol |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5497536/ https://ncbi.nlm.nih.gov/pubmed/28695150 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.410 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|